Drugs / 64-Cu-plerixafor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT02069080 | Feb 2014 → Jul 2018 | cancer | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64-Cu-plerixafor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02069080 ↗ |
| Action | Inhibit | “a specific inhibitor of CXCR4” NCT02069080 ↗ |
| Modality | Diagnostic / imaging agent | “evaluate (64)Cu-plerixafor as an imaging agent” NCT02069080 ↗ |
| Route | Intravenous | “administered an initial intravenous (IV) infusion of 64Cu-plerixafor” NCT02069080 ↗ |
| Target | CXCR4 | “a specific inhibitor of CXCR4” NCT02069080 ↗ |